Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR01312
|
|||||
Drug Name |
Paritaprevir
|
|||||
Synonyms |
(2R,6S,13aS,14aR,16aS,Z)-N-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide; ABT 450; ABT-450; ABT450; CHEMBL3391662; EX-A2278; OU2YM37K86; Paritaprevir; Paritaprevir [USAN:INN]; Paritaprevir(ABT-450); Paritaprevir(Veruprevir ABT-450); SCHEMBL3069964; UNII-OU2YM37K86; Veruprevir; Veruprevir [INN]; Veruprevir anhydrous
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Hepatitis C virus infection [ICD11: 1E50.2, 1E51.1] | Phase 2 | [1] | |||
Therapeutic Class |
Antiviral Agent
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C40H43N7O7S
|
|||||
Canonical SMILES |
CC1=CN=C(C=N1)C(=O)NC2CCCCCC=CC3CC3(NC(=O)C4CC(CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C75)C(=O)NS(=O)(=O)C8CC8
|
|||||
InChI |
InChI=1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1
|
|||||
InChIKey |
UAUIUKWPKRJZJV-QPLHLKROSA-N
|
|||||
CAS Number |
CAS 1216941-48-8
|
|||||
Pharmaceutical Properties | Molecular Weight | 765.9 | Topological Polar Surface Area | 198 | ||
Heavy Atom Count | 55 | Rotatable Bond Count | 7 | |||
Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 10 | |||
XLogP |
4.7
|
|||||
PubChem CID | ||||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
References | ||||||
1 | ClinicalTrials.gov (NCT01458535) A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Nave Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV) | |||||
2 | Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.